TNFRSF8 and classic Hodgkin lymphoma: Consequently, therapeutic strategies targeting these pathways, such as inhibitors of CD30 and immune checkpoint blockade with PD-1/PD-L1 inhibitors, are being explored to disrupt these interactions, offering promising avenues to improve outcomes for cHL patients [21,33,34].